Advanced search
Publication Cover
Clinical, Cosmetic and Investigational Dermatology Volume 16, 2023 - Issue
Submit an article Journal homepage
147
Views
0
CrossRef citations to date
0
Altmetric
COMMENTARY

Exploring the Quality-of-Life Impact, Disease Burden, and Management Challenges of GPP: The Provider and Patient Perspective [Podcast]

Jason E Hawkes1 Department of Dermatology, University of California at Davis, Sacramento, CA, USAView further author information
,
Dale V Reisner2 Patient Author, Yankton, SD, USAView further author information
&
Tina Bhutani3 Psoriasis and Skin Treatment Center, Department of Dermatology, University of California at San Francisco, San Francisco, CA, USACorrespondence[email protected]
View further author information
Pages 3333-3339 | Received 11 Oct 2023, Accepted 11 Oct 2023, Published online: 16 Nov 2023

References

  • Gooderham MJ, Van Voorhees AS, Lebwohl MG. An update on generalized pustular psoriasis. Expert Rev Clin Immunol. 2019;15(9):907–919. doi:10.1080/1744666X.2019.1648209
  • Bachelez H, Barker J, Burden AD, Navarini AA, Krueger JG. Generalized pustular psoriasis is a disease distinct from psoriasis vulgaris: evidence and expert opinion. Expert Rev Clin Immunol. 2022;18(10):1033–1047. doi:10.1080/1744666X.2022.2116003
  • Prinz JC, Choon SE, Griffiths CEM, et al. Prevalence, comorbidities and mortality of generalized pustular psoriasis: a literature review. J Eur Acad Dermatol Venereol. 2023;37(2):256–273. doi:10.1111/jdv.18720
  • Ly K, Beck KM, Smith MP, Thibodeaux Q, Bhutani T. Diagnosis and screening of patients with generalized pustular psoriasis. Psoriasis (Auckl). 2019;9:37–42. doi:10.2147/PTT.S181808
  • Tang S, Gong Y, Liu M, Yang D, Tang K. Do drug accessibility and OOP burden affect health-related quality of life of patients with chronic diseases? - EQ-5D-5L evaluation evidence from five districts in China. Front Public Health. 2021;9:656104. doi:10.3389/fpubh.2021.656104
  • Choon SE, Navarini AA, Pinter A. Clinical course and characteristics of generalized pustular psoriasis. Am J Clin Dermatol. 2022;23(Suppl 1):21–29. doi:10.1007/s40257-021-00654-z
  • Crowley JJ, Pariser DM, Yamauchi PS. A brief guide to pustular psoriasis for primary care providers. Postgrad Med. 2021;133(3):330–344. doi:10.1080/00325481.2020.1831315
  • Zheng M, Jullien D, Eyerich K. The prevalence and disease characteristics of generalized pustular psoriasis. Am J Clin Dermatol. 2022;23(Suppl 1):5–12. doi:10.1007/s40257-021-00664-x
  • Krueger J, Puig L, Thaci D. Treatment options and goals for patients with generalized pustular psoriasis. Am J Clin Dermatol. 2022;23(Suppl 1):51–64. doi:10.1007/s40257-021-00658-9
  • Reisner DV, Johnsson FD, Kotowsky N, Brunette S, Valdecantos W, Eyerich K. Impact of generalized pustular psoriasis from the perspective of people living with the condition: results of an online survey. Am J Clin Dermatol. 2022;23(Suppl 1):65–71. doi:10.1007/s40257-021-00663-y
  • Strober B, Leman J, Mockenhaupt M, et al. Unmet educational needs and clinical practice gaps in the management of generalized pustular psoriasis: global perspectives from the front line. Dermatol Ther. 2022;12(2):381–393. doi:10.1007/s13555-021-00661-2
  • Lofvendahl S, Norlin JM, Schmitt-Egenolf M. Economic burden of generalized pustular psoriasis in sweden: a population-based register study. Psoriasis (Auckl). 2022;12:89–98. doi:10.2147/PTT.S359011
  • Boehringer Ingelheim. FDA approves the first treatment option for generalized pustular psoriasis flares in adults; 2022 Available from: https://www.boehringer-ingelheim.us/press-release/fda-approves-first-treatment-option-generalized-pustular-psoriasis-flares-adults. Accessed June 13, 2023.
  • Boehringer Ingelheim. European Commission approves SPEVIGO® (spesolimab) for generalized pustular psoriasis flares; 2022. Available from: https://www.boehringer-ingelheim.com/human-health/skin-diseases/gpp/european-commission-approves-spevigo-spesolimab-generalized. Accessed June 13, 2023.
  • Bachelez H, Choon SE, Marrakchi S, et al. Trial of spesolimab for generalized pustular psoriasis. N Engl J Med. 2021;385(26):2431–2440. doi:10.1056/NEJMoa2111563
  • Morita A, Choon SE, Bachelez H, et al. Design of effisayil 2: a randomized, double-blind, placebo-controlled study of spesolimab in preventing flares in patients with generalized pustular psoriasis. Dermatol Ther (Heidelb). 2023;13(1):347–359. doi:10.1007/s13555-022-00835-6
  • Morita A, Strober B, Burden AD, et al. Efficacy and safety of subcutaneous spesolimab for the prevention of generalized pustular psoriasis flares (Effisayil 2): a multicenter, randomized, placebo-controlled trial. Lancet. 2023:19. doi:10.1016/S0140-6736(23)01378-8
  • Hanna ML, Singer D, Bender SD, Valdecantos WC, Wu JJ. Characteristics of hospitalizations and emergency department visits due to generalized pustular psoriasis in the United States. Curr Med Res Opin. 2021;37(10):1697–1703. doi:10.1080/03007995.2021.1951192

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.